Biopharmaceutical pipelines utilizing automated synthetic biology platforms reported a 45% reduction in target discovery timelines during clinical-stage candidate screening. The integration of high-throughput sequencing with predictive algorithms is streamlining the identification of neoantigen targets.
Commercial Viability and Scale
While early-stage development efficiency has improved, drug developers face ongoing regulatory hurdles regarding manufacturing standardization. Investment in automated bioreactor infrastructure remains critical for scaling personalized immunotherapies sustainably.